TILS

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

Retrieved on: 
пятница, мая 24, 2024
News, HER2, Investment, Pfizer, Chimera, Hallucination, Pancreas, Blood, Pancreatic cancer, Breast cancer, Anxiety, Medicine, Proteolysis, Therapy, TSX, Nucleic acid thermodynamics, Survival, TIL, PALM, ONC, TILS, Magnetic resonance imaging, ABBV, NASAR, MD, Gemcitabine, PFE, Immunotherapy, PDAC, ARVN, DSM-IV codes, Safety, FOLFIRINOX, Psychiatry, Research, Cancer, Rhinitis, ASCO, Society, Patient, Doctor of Philosophy, DNA, Prevalence, Diagnosis, Growth, Social media, Pancreatic Cancer Action Network, Abstract, Personalized medicine, ESMO, Oncolytics Biotech, Classic, Oncology, Annual general meeting, Pharmaceutical industry

With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts.

Key Points: 
  • With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts.
  • The report said: “This growth is driven by increasing instances of pancreatic cancer and higher investments in pancreatic oncology research.
  • In recent years, the pancreatic cancer market has experienced steady growth, largely driven by the increasing prevalence of pancreatic cancer cases globally.
  • BioSpace concluded: “Several notable trends are shaping the pancreatic cancer market.

Incendia Therapeutics Announces Upcoming Presentation with PathAI at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
четверг, мая 23, 2024
Other Health, Research, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Science, Health, Patient, Doctor of Philosophy, CPI, The Cancer Genome Atlas, Survival, Lymphocyte, TIL, Data, TILS, Translational medicine, TME, IPS, Tumor microenvironment, Lung cancer, Therapy, PFS, Senior, AI, Neoplasm, IIP, IP, Biomarker, ASCO, Society, Classification, Haematoxylin, Dip, TCGA, Annual general meeting

Incendia Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will present data in collaboration with PathAI, a leading AI-powered precision pathology company at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, Illinois.

Key Points: 
  • Incendia Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will present data in collaboration with PathAI, a leading AI-powered precision pathology company at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, Illinois.
  • “The data demonstrate the correlation between immune phenotypes predicted from hematoxylin and eosin (H&E)-stained whole slide images and survival following checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC).
  • In the clinical cohort, cancer tumor infiltrating lymphocytes density and fraction of hot epithelial patches were significantly associated with (PFS) (HR=0.64, q=0.04 and HR=0.69, q=0.04, respectively).
  • Notably, in PD-L1(-) patients (N=43, tumor proportion score ≤1%), iIP patients had longer PFS than eIP and dIP patients (HR=0.35, p=0.02).

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
четверг, мая 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Retrieved on: 
четверг, мая 9, 2024
SNF, FOLFIRINOX, DOI, Blood, Pancreatic cancer, Poster, TILS, Immunotherapy, TSX, PR, MD, Tumor microenvironment, AB, ONC, Roche, PDAC, Cancer, Patient, Pancreatic Cancer Action Network, AIO, Medicine, SWI, MMSc, Ethics, PD, Therapy, SAN, Anal cancer, TME, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. The chemotherapy regimens of mFOLFIRINOX or gemcitabine + nab-paclitaxel are the two most common standards of care for pancreatic cancer.1 Oncolytics has already reported data with the combination of gemcitabine and nab-paclitaxel (link to the PR, link to the poster) that surpassed historical outcomes.2-5 Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.

Key Points: 
  • This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC).
  • It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.

Epsilon Reports First Quarter 2024 Results

Retrieved on: 
среда, мая 8, 2024
Permian, NRI, Central Time, Investment, News, Natural gas, TILS, MMBTU, Conference, Webcast, PDP, TIL, Acquisition, Interest, Cubic foot, Oil

Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.

Key Points: 
  • Epsilon’s capital expenditures were $21.4 million for the quarter ended March 31, 2024.
  • In addition, our operating partner in PA curtailed production in response to low realized gas prices in the first quarter (quantified above).
  • The Company will host a conference call to discuss its results on Thursday, May 9, 2024 at 9:30 a.m. Central Time (10:30 a.m. Eastern Time).
  • Participants should ask to be joined to the “Epsilon Energy First Quarter 2024 Earnings Conference Call.”
    A webcast can be viewed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=BtayVC7k .

Civitas Resources Reports First Quarter 2024 Results

Retrieved on: 
четверг, мая 2, 2024
Oil, Gas, Energy, Permian, Acquisition, Natural gas, NGL, TIL, TILS, Civitas

As a result of operational efficiencies achieved in the Permian Basin, Civitas drilled three net miles (1.5 wells) and completed six net miles (3 wells) more than planned in the first quarter.

Key Points: 
  • As a result of operational efficiencies achieved in the Permian Basin, Civitas drilled three net miles (1.5 wells) and completed six net miles (3 wells) more than planned in the first quarter.
  • “This quarter was the first reporting period that all our new businesses were together, and our results highlight just the beginning of Civitas' bright future ahead.
  • Sales volume for the first quarter 2024 were higher than expected at 336 MBoe/d, which benefited from continued strong well performance and accelerated turn-in-line ("TIL") timing.
  • NGL realizations per barrel represented 29% of West Texas Intermediate crude oil in the first quarter of 2024.

Turnstone Biologics Appoints William Waddill to its Board of Directors

Retrieved on: 
вторник, апреля 16, 2024
University, CFO, LLP, Champaign–Urbana metropolitan area, Certification, Arrowhead Pharmaceuticals, TILS, PwC, Biotechnology Innovation Organization, BIO, Selection, TIL, SVP, Senior, Patient, OncoMed, Therapy, Biotechnology, SAN, Pharmaceutical industry

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.

Key Points: 
  • SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
  • The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.
  • “I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer.
  • “Will is a highly accomplished biotechnology executive and Board member, and his impressive track record and deep operational and financial acumen make him a valuable addition to our Board.